Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immun...

Full description

Bibliographic Details
Main Authors:	O'Hara, G, Duncan, C, Ewer, K, Collins, K, Elias, S, Halstead, F, Goodman, A, Edwards, N, Reyes-Sandoval, A, Bird, P, Rowland, R, Sheehy, S, Poulton, I, Hutchings, C, Todryk, S, Andrews, L, Folgori, A, Berrie, E, Moyle, S, Nicosia, A, Colloca, S, Cortese, R, Siani, L, Lawrie, A, Gilbert, S, Hill, A
Format:	Journal article
Language:	English
Published:	Oxford University Press 2012

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

Similar Items